Charles D. Burger, MD: Portopulmonary hypertension is a subgroup of Group 1 pulmonary arterial hypertension [PAH], and it occurs in the setting of hepatic cirrhosis or end-stage liver disease ...

Portopulmonary Hypertension (High Blood Pressure in Lung Arteries) What Happens? Portopulmonary hypertension emerges when high pressure in the portal system affects the arteries in the lungs.

Portopulmonary hypertension is characterized by a mean pulmonary artery pressure > 25 mm Hg at rest or > 30 mm Hg with exercise, increased pulmonary vascular resistance (> 240 dynes/sec/cm-5), and ...

Intrapulmonary vascular dilatations occurred more commonly in patients with portopulmonary hypertension and were associated with decreased overall survival, according to study data published in ...

Patients with portopulmonary hypertension, for example, can come off PAH–targeted therapy after transplant, meaning some patients can even be cured of their portopulmonary hypertension with ...

Portopulmonary hypertension is associated with mortality that is higher than the risk predicted by the Model for End-Stage Liver Disease (MELD) score, the measure used to determine status on the ...

Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH). PoPH occurs in approximately 15% of patients with PAH, and is reportedly found in 2-6% of patients with ...

Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH). PoPH occurs in approximately 15% of patients with PAH, and is reportedly found in 2-6% of patients with ...

Medically reviewed by Christopher Lee, MD Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a ...

Portopulmonary hypertension is a relatively common complication of end-stage liver disease. Mild disease is not a contraindication to liver transplantation, but moderate disease is associated with ...

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.